Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Tolerance of TQ-A3326 in Healthy Participants
NCT03714568Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatitis C (HCV) comparing TQ-A3326 with Placebo (2 arms). Primary endpoints: Number of Participants With Serious Adverse Events, Number of Participants With Clinically Significant Change From Baseline in Vital Sign Measurements and 1 more. Status: unknown.
02
Drugs
TQ-A3326
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03714568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03714568.